Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.

Imago BioSciences (IMGO) News Today

Imago BioSciences logo
Merck: Better Times Ahead On Approvals And Outlook
Clarus Lifesciences III, L.P.'s Net Worth
Anixa Biosciences Inc ANIX
Merck To Complete Acquisition Of Imago
Merck is best performing large U.S. pharma of 2022
Imago BioSciences, Inc. stock logo
Laura G. Eichorn Sells 3,100 Shares of Imago BioSciences, Inc. (NASDAQ:IMGO) Stock
Imago BioSciences, Inc. (NASDAQ:IMGO - Get Rating) CFO Laura G. Eichorn sold 3,100 shares of Imago BioSciences stock in a transaction that occurred on Tuesday, December 27th. The stock was sold at an average price of $35.93, for a total value of $111,383.00. Following the completion of the sale, the chief financial officer now directly owns 207,737 shares in the company, valued at approximately $7,463,990.41. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Imago BioSciences, Inc. stock logo
Imago BioSciences, Inc. (NASDAQ:IMGO) Given Average Recommendation of "Hold" by Analysts
Shares of Imago BioSciences, Inc. (NASDAQ:IMGO - Get Rating) have received a consensus rating of "Hold" from the seven analysts that are covering the firm, Marketbeat Ratings reports. Six analysts have rated the stock with a hold rating. The average 1-year price target among analysts that have iss
Imago BioSciences, Inc. stock logo
Imago BioSciences, Inc. (NASDAQ:IMGO) Insider Jennifer Peppe Sells 119,422 Shares
Imago BioSciences, Inc. (NASDAQ:IMGO - Get Rating) insider Jennifer Peppe sold 119,422 shares of the firm's stock in a transaction that occurred on Thursday, December 15th. The shares were sold at an average price of $35.80, for a total transaction of $4,275,307.60. Following the sale, the insider now directly owns 148,809 shares of the company's stock, valued at approximately $5,327,362.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Imago BioSciences, Inc. stock logo
Imago BioSciences, Inc. (NASDAQ:IMGO) Short Interest Down 79.4% in November
Imago BioSciences, Inc. (NASDAQ:IMGO - Get Rating) was the recipient of a large decline in short interest during the month of November. As of November 30th, there was short interest totalling 706,100 shares, a decline of 79.4% from the November 15th total of 3,430,000 shares. Approximately 3.5% of the shares of the company are sold short. Based on an average daily volume of 618,500 shares, the days-to-cover ratio is currently 1.1 days.
Merck Commences Tender Offer To Acquire Imago BioSciences
Analyst Ratings for Imago BioSciences
Imago BioSciences, Inc. stock logo
Imago BioSciences, Inc. (NASDAQ:IMGO) Forecasted to Post Q2 2023 Earnings of ($0.63) Per Share
Imago BioSciences, Inc. (NASDAQ:IMGO - Get Rating) - Equities researchers at Wedbush issued their Q2 2023 earnings per share (EPS) estimates for Imago BioSciences in a report issued on Monday, November 21st. Wedbush analyst R. Driscoll forecasts that the company will post earnings per share of ($
Expert Ratings for Imago BioSciences
What 5 Analyst Ratings Have To Say About Imago BioSciences
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck
Merck to Buy Imago, Shares Gain
Merck to buy Imago Biosciences for $1.35 billion
Imago BioSciences, Inc. stock logo
Imago BioSciences, Inc. (NASDAQ:IMGO) Forecasted to Earn FY2022 Earnings of ($1.94) Per Share
Imago BioSciences, Inc. (NASDAQ:IMGO - Get Rating) - Stock analysts at Jefferies Financial Group lowered their FY2022 EPS estimates for Imago BioSciences in a research report issued on Thursday, November 10th. Jefferies Financial Group analyst M. Raycroft now expects that the company will earn ($
Imago BioSciences, Inc. stock logo
Amy E. Tapper Sells 750 Shares of Imago BioSciences, Inc. (NASDAQ:IMGO) Stock
Imago BioSciences, Inc. (NASDAQ:IMGO - Get Rating) insider Amy E. Tapper sold 750 shares of the business's stock in a transaction that occurred on Wednesday, November 2nd. The stock was sold at an average price of $17.90, for a total value of $13,425.00. Following the completion of the transaction, the insider now directly owns 119,047 shares in the company, valued at $2,130,941.30. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Get Imago BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMGO and its competitors with MarketBeat's FREE daily newsletter.

Shocking footage from Bill Gates’ $100,000,000,000 AI Bet (Ad)

If you missed out on Nvidia, watch this BEFORE November 19th.

Click here for the full video

IMGO Media Mentions By Week

IMGO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

IMGO
News Sentiment

0.00

0.54

Average
Medical
News Sentiment

IMGO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

IMGO Articles
This Week

0

0

IMGO Articles
Average Week

Get Imago BioSciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMGO and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:IMGO) was last updated on 11/16/2024 by MarketBeat.com Staff
From Our Partners